Platelet aggregation and serum adenosine deaminase (ADA) activity in pregnancy associated with diabetes, hypertension and HIV

Abstract

Platelet aggregation and adenosine deaminase (ADA) activity were evaluated in pregnant women living with some disease conditions including hypertension, diabetes mellitus and human immunodeficiency virus infection. The subject population is consisted of 15 non‐pregnant healthy women [control group (CG)], 15 women with normal pregnancy (NP), 7 women with hypertensive pregnancy (HP), 10 women with gestational diabetes mellitus (GDM) and 12 women with human immunodeficiency virus‐infected pregnancy (HIP) groups. The aggregation of platelets was checked using an optical aggregometer, and serum ADA activity was determined using the colorimetric method. After the addition of 5 µM of agonist adenosine diphosphate, the percentage of platelet aggregation was significantly (p < 0·05) increased in NP, HP, GDM and HIP groups when compared with the CG, while the addition of 10 µM of the same agonist caused significant (p < 0·05) elevations in HP, GDM and HIP groups when compared with CG. Furthermore, ADA activity was significantly (p < 0·05) enhanced in NP, HP, GDM and HIP groups when compared with CG. In this study, the increased platelet aggregation and ADA activity in pregnancy and pregnancy‐associated diseases suggest that platelet aggregation and ADA activity could serve as peripheral markers for the development of effective therapy in the maintenance of homeostasis and some inflammatory process in these pathophysiological conditions. Copyright © 2016 John Wiley & Sons, Ltd.

Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases

“…Indeed, ecto-enzymes engaged in adenosine metabolism have been recognized on the surface of platelets, including ATP-degrading ecto-nucleoside triphosphate diphosphohydrolase (eNTPDase) and ecto-nucleotide pyrophosphatase/phosphodiesterase (eNPP), adenosine-producing ecto-5′-nucleotidase (e5′NT) and adenosine-degrading eADA [ 132 ]. Suoza Vdo et al revealed increased activities of eNPP and e5′NT and decreased eADA activity in platelets of patients with Chagas disease contributed to decreased platelet aggregation, suggesting that the purinergic system is significantly involved in the thromboregulation [ 132 ], whereas, Leal et al demonstrated that serum ADA activity positively correlated with increased platelet aggregation in pregnant women with an increased risk of cardiovascular disease [ 133 ]. Therefore, the increase in ADA activity can contribute to adenosine depletion followed by the activation of a pro-aggregatory phenotype.…”

Increased Graft Survival through Ectonucleotidases Modulation in Platelets and Lymphocytes of Kidney Transplanted Patients

“…Adenosine is a potent modulator of lymphocyte development, proliferation and activity, and its effect depends both on its bioavailability and on cell surface P1 receptors expression [31]. In humans, the absence of ADA activity results in severe lymphopenia and immunodeficiency [32]. The observed decrease in ADA activity in these cells in our study, and the consequent accumulation of adenosine, may be related to graft rejection and resistance.…”

The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases

“…Original studies have shown increased platelet aggregation as a result of high ADA activity and expression and lack of adenosine in pregnancy hypertensive [ 112 , 113 ]. It was indeed suggested that ADA activity as well as platelet aggregation could serve as peripheral markers for the development of therapy for the maintenance of homeostasis and inflammatory processes in hypertension and hypertension-associated pathologies [ 108 , 113 ]. In contrast, Iriyama et al have analyzed adenosine metabolism using two different animal models of preeclampsia [ 114 ].…”